Search This Blog

Thursday, April 30, 2026

EBS ups net income, EBITDA outlook

 

Emergent BioSolutions posts stronger-than-guided Q1 2026 results with $156.1M revenue and $6.8M net income, updates full-year 2026 outlook

  • Singapore approves expanded indication for Emergent BioSolutions' ACAM2000 vaccine for mpox prevention in high‑risk adults.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)